On Tuesday, Legend Biotech Corp ADR (NASDAQ: LEGN) was 2.32% up from the session before settling in for the closing price of $43.61. A 52-week range for LEGN has been $38.60 – $70.13.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 50.60% over the past five years. When this article was written, the company’s average yearly earnings per share was at 39.33%. With a float of $181.45 million, this company’s outstanding shares have now reached $181.91 million.
Let’s look at the performance matrix of the company that is accounted for 1826 employees. In terms of profitability, gross margin is 56.67%, operating margin of -76.29%, and the pretax margin is -62.95%.
Legend Biotech Corp ADR (LEGN) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Legend Biotech Corp ADR stocks. The insider ownership of Legend Biotech Corp ADR is 0.94%, while institutional ownership is 50.06%. The most recent insider transaction that took place on Sep 25 ’24, was worth 66,326. Before that another transaction happened on Sep 20 ’24, when Company’s Officer proposed sale 90,060 for $48.91, making the entire transaction worth $4,405,003.
Legend Biotech Corp ADR (LEGN) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 39.33% per share during the next fiscal year.
Legend Biotech Corp ADR (NASDAQ: LEGN) Trading Performance Indicators
You can see what Legend Biotech Corp ADR (LEGN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.78. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 17.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.57, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -0.50 in one year’s time.
Technical Analysis of Legend Biotech Corp ADR (LEGN)
Legend Biotech Corp ADR (NASDAQ: LEGN) saw its 5-day average volume 1.41 million, a positive change from its year-to-date volume of 1.07 million. As of the previous 9 days, the stock’s Stochastic %D was 32.21%. Additionally, its Average True Range was 2.24.
During the past 100 days, Legend Biotech Corp ADR’s (LEGN) raw stochastic average was set at 21.23%, which indicates a significant decrease from 45.25% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 29.86% in the past 14 days, which was lower than the 48.32% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $48.51, while its 200-day Moving Average is $51.88. Nevertheless, the first resistance level for the watch stands at $46.78 in the near term. At $48.95, the stock is likely to face the second major resistance level. The third major resistance level sits at $50.10. If the price goes on to break the first support level at $43.46, it is likely to go to the next support level at $42.31. Assuming the price breaks the second support level, the third support level stands at $40.14.
Legend Biotech Corp ADR (NASDAQ: LEGN) Key Stats
There are 182,305K outstanding shares of the company, which has a market capitalization of 8.17 billion. As of now, sales total 285,140 K while income totals -518,250 K. Its latest quarter income was 186,520 K while its last quarter net income were -18,200 K.
